-
Kenya's economy faces climate change risks: World Bank
-
Brussels to unveil 'EU Inc' pan-European company status
-
Brazil starts to restrict minors' access to social media
-
US Fed expected to hold rates steady as Iran war's shockwaves ripple
-
Oscars audience drops, viewing figures show
-
Nvidia says restarting production of China-bound chips
-
US airlines still see strong demand as jet fuel worries loom
-
Milei blasts Iran on anniversary of attack on Israeli embassy
-
Leftist New York mayor under pressure on Irish unity question
-
Iran vets friendly ships for Hormuz passage: trackers
-
Ships in Gulf risk shortages on board, industry warns
-
New particle discovered by Large Hadron Collider
-
US Fed expected to keep rates steady as Iran war impact looms
-
Kerr 'frustrated' at six-figure sum owed to him by Johnson's failed Grand Slam Track
-
Oil prices climb as fresh strikes target infrastructure
-
Belgian diplomat ordered to stand trial over 1961 Congo leader murder
-
War threatens Gulf's dugongs, turtles and birds
-
Germany targets oil firms to prevent wartime price gouging
-
EU to help reopen blocked oil pipeline in Ukraine
-
Cash handouts, fare hikes as Philippines battles soaring fuel costs
-
Indonesia weighs response to price pressures from Middle East war
-
In Hollywood, AI's no match for creativity, say top executives
-
Nvidia chief expects revenue of $1 trillion through 2027
-
Nvidia making AI module for outer space
-
Migrant workers bear brunt of Iran attacks in Gulf
-
Trump vows to 'take' Cuba as island reels from oil embargo
-
Equities rise on oil easing, with focus on Iran war and central banks
-
Nvidia rides 'claw' craze with AI agent platform
-
Damaged Russian tanker has 700 tonnes of fuel on board: Moscow
-
Talks towards international panel to tackle 'inequality emergency' begin at UN
-
EU talks energy as oil price soars
-
Swiss government rejects proposal to limit immigration
-
Ingredients of life discovered in Ryugu asteroid samples
-
Why Iranian drones are hard to stop
-
France threatens to block funds for India over climate inaction
-
"So proud": Irish hometown hails Oscar winner Jessie Buckley
-
European bank battle heats up as UniCredit swoops for Commerzbank
-
Italian bank UniCredit makes bid for Germany's Commerzbank
-
AI to drive growth despite geopolitics, Taiwan's Foxconn says
-
Filipinas seek abortions online in largely Catholic nation
-
'One Battle After Another' wins best picture Oscar
-
South Koreans bask in Oscars triumph for 'KPop Demon Hunters'
-
'One Battle After Another' dominates Oscars
-
Norway's Oscar winner 'Sentimental Value': a failing father seeks redemption
-
Indonesia firms in palm oil fraud probe supplied fuel majors
-
Milan-Cortina Paralympics end as a 'beacon of unity'
-
It's 'Sinners' vs 'One Battle' as Oscars day arrives
-
Oscars night: latest developments
-
US Fed expected to hold rates steady as Iran war roils outlook
-
It's 'Sinners' v 'One Battle' as Oscars day arrives
'Geneva patient' the latest in long-term remission from HIV
A man dubbed the "Geneva patient" is the latest person with HIV to be declared in long-term remission -- however he did not receive a transplant with a virus-blocking gene mutation like previous cases, researchers said Thursday.
Five people have previously been considered "cured" of HIV: the Berlin, London, Duesseldorf, New York and City of Hope, California patients.
All had bone marrow transplants to treat serious cases of cancer, receiving stem cells from a donor with a mutation of the CCR5 gene. This mutation is known to block HIV from entering the body's cells.
In 2018, the Geneva patient similarly received a stem cell transplant to treat a particularly aggressive form of leukaemia.
But this time the transplant came from a donor who did not carry the CCR5 mutation, French and Swiss researchers told a press conference in the Australian city of Brisbane as part of an AIDS conference that begins at the weekend.
This means that the virus is still able to enter the patient's cells.
However, 20 months after the man stopped taking antiretroviral treatment -- which reduces the amount of HIV in the blood -- doctors at Geneva University Hospitals have not found a trace of the virus in his system, the researchers said.
While they cannot rule out that the man's HIV will return, the researchers said they consider him to be in long-term remission.
"What is happening to me is magnificent, magical," the Geneva patient said in a statement.
The patient, a white man who chose not to be named, was diagnosed with HIV in 1990.
He had been on antiretrovirals until November 2021, when his doctors advised him to stop taking the treatment after the bone marrow transplant.
- 'Promising' -
Two previous cases, known as the Boston patients, had also received normal or "wild type" stem cells during their transplants. But in both cases, HIV returned a few months after they stopped taking antiretrovirals.
Asier Saez-Cirion, a scientist at France's Pasteur Institute who presented the Geneva patient case in Brisbane, told AFP that if there was still no sign of the virus after 12 months "the probability that it will be undetectable in the future increases significantly".
There were a couple of possible explanations for why the Geneva patient remains HIV free, Saez-Cirion said.
"In this specific case, perhaps the transplant eliminated all the infected cells without the need for the famous mutation," he said.
"Or maybe his immunosuppressive treatment, which was required after the transplant, played a role."
Sharon Lewin, the president of the International AIDS Society holding the HIV science conference in Brisbane, said the case was "promising".
"But we learned from the Boston patients that even a single" particle of the virus can lead to HIV rebounding, she cautioned.
"This particular individual will need to be watched closely over the next months and years."
While these cases of long-term remission raise hopes that one day HIV can truly be cured, the brutal and risky bone marrow transplant procedure is not an option for the millions of people living with the virus around the world.
It is instead a last-ditch attempt to treat life-threatening cancer in people who also have HIV.
However, there are hopes that the remission cases could point towards new avenues of research, such as the potential role played by immunosuppressive treatments.
Saez-Cirion said the case had also encouraged the researchers to continue studying innate immune cells, which act as the first line of defence against various pathogens, and could help control the virus.
For his part, the Geneva patient said he was now "looking to the future".
H.Cho--CPN